Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of the treatment phase of the lead-in study, LAC-MD-31~* Written informed consent obtained from the patient before the initiation of any study specific procedures~* No medical contraindication as judged by the PI~* Compliance with LAC-MD-31 study procedures and IP dosing.~Exclusion Criteria:~* No specific exclusion criteria

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose
- 2 (Type: EXPERIMENTAL): Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose
- 3 (Type: ACTIVE_COMPARATOR): Aclidinium bromide 400 μg
- 4 (Type: ACTIVE_COMPARATOR): Formoterol Fumarate 12 μg
- 5 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).